Clinical NLP, PubGene Clinical trials in Coremine Oncology Text processing and information extraction for surgery planning form

Size: px
Start display at page:

Download "Clinical NLP, PubGene Clinical trials in Coremine Oncology Text processing and information extraction for surgery planning form"

Transcription

1 Clinical NLP, PubGene Clinical trials in Coremine Oncology Text processing and information extraction for surgery planning form November 2017 Dag Are Steenhoff Hov, PubGene AS 1

2 PubGene, founded 2001 ArrayIt H25K microarray Integration of structured and unstructured information Interpretation of biomedical analysis data General information Specialized information analysis Scientific Literature Coremine Networks COREMINE Oncology COREMINE Medical COREMINE Platform 2

3 Clinical NLP in PubGene - examples Clinical trials in Coremine Oncology PubGene in Ahus Optique Courtesy of DNV-GL (Tore Hartvigsen) 3

4 Coremine Oncology AIM: To enable oncologists to make better treatment decisions HOW: Combine data from relevant sources to aid interpretation of oncogenomics data from NGS and other platforms Input: Somatic mutations, copy number changes, gene expression, or similar quantity Output: Gene/biomarker annotations, related drugs and drug sensitivity, pathways, clinical trials, etc. 4

5 Coremine Oncology Our Scope We focus on: Analysis of called events ; assumed that normalization and data quality considerations have been taken care of Collecting and integrating information for interpretation Linking to potentially relevant treatments Linking to clinical trials related to the input data 5

6 Coremine Oncology Currently three types of input data: (Somatic) mutations Copy number changes gene expression Analysis/Interpretation module to display information (annotations) about Mutation Gene/Protein Protein Domains Summary module to show patient level information with respect to: Statistics on mutations Related drugs for targets with change (in progress: also biomarker and sensitivity info) Pathways for targets with change Relevant clinical trials for aberrations 6

7 Example Somatic mutations input data Input for Coremine Oncology, case from lung cancer Chromosome number Position Reference nucleotide Alternate nucleotide 7

8 View of imported data file

9 Mutation annotation 1 patient - 1 missense mutation

10 10

11 Clinical Trials for Cetuximab 11

12 Clinical Trials for biomarkers AIM: To map biomarkers from patient data to relevant clinical trials METHOD: Identify how biomarkers are mentioned (referred to) in clinical trials Download and index data from clinicaltrials.gov Develop dictionaries of biomarkers and methods for detecting these in trial descriptions Focus on eligibility CHALLENGES Text mining is difficult! Biomarkers are described, or referred to in many ways Ultimately, we want to identify biomarkers related to eligibility, but this is not straightforward Complicated logic in inclusion/exclusion criteria, e.g., negation Also need to check title, description, and condition for biomarkers 12

13 Clinical Trials text data mining Compiled several lists of biomarkers of different types: Single-Nucleotide mutations (Cosmic) Polymorphisms Fusion genes Gene regulation (Exp-up/down) Copy number changes Several strategies for finding these in text: Detect explicit mentions Detect patterns based on gene name and marker type, e.g., GENE amplification GENE activating mutation Curated list of cancer types matched with conditions Statistics for patterns Expression: 135 CNV: 32 Other (positive/negative): 20/10 Mutation: 37 Fusion/rearrangement/translocation: 10 Indexing statistics 5350 trials with at least one biomarker 855 different biomarkers with hits Top markers: BCR/ABL1 (907), ERBB2 positive (725), ERBB2 negative (603), ESR1 positive (467), ERBB2 exp-up (403) 13

14 Clinical Trials for example case NSCLC and Erlotinib 14

15 Clinical Trials for copy number data (CNV) 15

16 Trials matching patient biomarkers and disease Cancer type, e.g., NSCLC Filter Manual curation Domain knowledge Clinical Trials GUI or command line CNA SNP EXP INDEL SNA FUSION 16

17 Clinical Trials for combined data NSCLC BRAF G469A BRAF D594G BRAF V600E EGFR T790M KIF5B/RET CD74/ROS1 KIF5B/ALK BCR/ABL1 17

18 Details from Clinical Trial information NCT

19 Clinical Trials matching to patient data Various levels of stringency for matching trial to patient Perfect match Other alteration (incl. same effect) Same gene (other biomarker) Related gene S = weighted sum of scores Biomarker specific scoring models due to different prioritization of relevance of other alterations AIM: To better map/identify other alterations with same/similar effect, e.g., amplification/up-regulation with activating mutation Example: Patient ERBB2 Exp up Trial: 1. Perfect match: ERBB2 Exp up 2. Same effect: ERBB2 CNV gain 3. Similar effect: ERBB2 Positive 4. Other alteration: ERBB2 mutation 5. Likely opposite effect: ERBB2 Neg. 6. Opposite effect: ERBB2 Exp down or, ERBB2 CNV loss 7. Gene Only: ERBB2 8. Related Gene: EGFR 19

20 Clinical NLP in PubGene - examples PubGene in Ahus Optique Courtesy of DNV-GL (Tore Hartvigsen) 20

21 Akershus University Hospital (Ahus) Optique project. Increase patient security by providing easier access to existing information Courtesy of DNV-GL (Tore Hartvigsen) Human touch and empathy with professional skill

22 The Surgery Planning Form is completed in 3 Stages Surgery Planning Form ( The Green Form ) Stage 1: Examination Stage 2: Preparations DIPS Ahus Structured data Text Metavision Ahus Metavision O Metavision I Metavision DKS Stage 3: Check/ QA Additional systems System System To complete the form, data must be collected from a number of systems! This is today done manually. Courtesy of DNV-GL (Tore Hartvigsen) 22

23 Leave the data in the source systems! Expert users «Ordinary» users Researchers/ Analysts A semantic IT solution and ontology for clinical use in Health Care Data warehousing is an option Ahus research Databases. Metavision O Metavision I Metavision DKS Ahus production databases DIPS DIPS (EPJ) (EPJ) (EPJ) Metav DIPS Courtesy of DNV-GL (Tore Hartvigsen) 23

24 We want to «lift» the data out of the silos! Expert users «Ordinary» users A semantic IT solution and ontology for clinical use in Health Care Structured data Unstructured data (text) Solutions provided by the Optique project Text mining Courtesy of DNV-GL (Tore Hartvigsen) 24

25 PubGene in Ahus Optique, information extraction Unstructured information Height 1,83 m Fields ASA BMI Height Weight Puls Blood pressure Temperature Diagnose codes Treatment codes Structured information name=height, type=int, unit=cm, value=183 25

26 PubGene i Ahus Optique, allergy information 26

27 PubGene i Ahus Optique, status on smoking Sentence Røyker. Røyker om dagen. Ifølge datter erhan også storrøyker, 40/ dag siste 50 år. Røykeplaster? Tidligere storrøyker. Ikke røyker og drikker ikke alkohol, tidligere, måteholdent alkoholbruk. Eks-røyker, lite alkohol. Status Yes Yes Yes Uncertain Stopped No Stopped Text analysis Separate text in sentences, detection of sentences containing røyke, røyki, røykt Classification of sentences based on recognition of keywords and word or sentence patterns NB: Based on a small database 27

28 Ahus Optique Screenshots Courtesy of DNV-GL (Tore Hartvigsen) 28

29 Courtesy of DNV-GL (Tore Hartvigsen)

30 Page for surgery planning form Courtesy of DNV-GL (Tore Hartvigsen)

31 Courtesy of DNV-GL (Tore Hartvigsen)

32 Courtesy of DNV-GL (Tore Hartvigsen) BMI

33 Courtesy of DNV-GL (Tore Hartvigsen)

34 Courtesy of DNV-GL (Tore Hartvigsen)

35 Courtesy of DNV-GL (Tore Hartvigsen)

36 Courtesy of DNV-GL (Tore Hartvigsen)

37 Allergy Courtesy of DNV-GL (Tore Hartvigsen)

38

39 Smoking Courtesy of DNV-GL (Tore Hartvigsen)

40 Courtesy of DNV-GL (Tore Hartvigsen)

41 Courtesy of DNV-GL (Tore Hartvigsen) Surgery planning form

42 Further development, text processing/analysis A large set of options and potential Far more effective collection of more relevant information, e.g., by filling surgery forms ( The green form ) Improved quality through automatic detection of errors in documents and control of consistency with structured data Further steps for Ahus Optique Simple: Extraction of more static fields, like lab results Information about medication Information on heart function, lung function Exploit document structure and information on document types 42

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits

AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect

More information

Knowledge networks of biological and medical data An exhaustive and flexible solution to model life sciences domains

Knowledge networks of biological and medical data An exhaustive and flexible solution to model life sciences domains Knowledge networks of biological and medical data An exhaustive and flexible solution to model life sciences domains Dr. Sascha Losko, Dr. Karsten Wenger, Dr. Wenzel Kalus, Dr. Andrea Ramge, Dr. Jens Wiehler,

More information

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1 An example of the gene-term-disease network automatically generated by Phenolyzer web server for 'autism'. The largest word represents the user s input term, Autism. The pink round

More information

Session 4 Rebecca Poulos

Session 4 Rebecca Poulos The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20

More information

Transform genomic data into real-life results

Transform genomic data into real-life results CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for

More information

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R

Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB

More information

Session 4 Rebecca Poulos

Session 4 Rebecca Poulos The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 28

More information

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB

AVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation

More information

Integrated Analysis of Copy Number and Gene Expression

Integrated Analysis of Copy Number and Gene Expression Integrated Analysis of Copy Number and Gene Expression Nexus Copy Number provides user-friendly interface and functionalities to integrate copy number analysis with gene expression results for the purpose

More information

Building Cognitive Computing for Healthcare

Building Cognitive Computing for Healthcare Building Cognitive Computing for Healthcare Boston University Digital Health Initiative Round Table February 27 th 2017 Patrick McNeillie M.D. Clinical Lead and Senior Architect on Watson for Genomics

More information

KEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl

KEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016

More information

How can Natural Language Processing help MedDRA coding? April Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics

How can Natural Language Processing help MedDRA coding? April Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics How can Natural Language Processing help MedDRA coding? April 16 2018 Andrew Winter Ph.D., Senior Life Science Specialist, Linguamatics Summary About NLP and NLP in life sciences Uses of NLP with MedDRA

More information

Module 3: Pathway and Drug Development

Module 3: Pathway and Drug Development Module 3: Pathway and Drug Development Table of Contents 1.1 Getting Started... 6 1.2 Identifying a Dasatinib sensitive cancer signature... 7 1.2.1 Identifying and validating a Dasatinib Signature... 7

More information

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies 2017 Contents Datasets... 2 Protein-protein interaction dataset... 2 Set of known PPIs... 3 Domain-domain interactions...

More information

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018

NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018 Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as

More information

Analysis with SureCall 2.1

Analysis with SureCall 2.1 Analysis with SureCall 2.1 Danielle Fletcher Field Application Scientist July 2014 1 Stages of NGS Analysis Primary analysis, base calling Control Software FASTQ file reads + quality 2 Stages of NGS Analysis

More information

Innovative Risk and Quality Solutions for Value-Based Care. Company Overview

Innovative Risk and Quality Solutions for Value-Based Care. Company Overview Innovative Risk and Quality Solutions for Value-Based Care Company Overview Meet Talix Talix provides risk and quality solutions to help providers, payers and accountable care organizations address the

More information

Cancer Informatics Lecture

Cancer Informatics Lecture Cancer Informatics Lecture Mayo-UIUC Computational Genomics Course June 22, 2018 Krishna Rani Kalari Ph.D. Associate Professor 2017 MFMER 3702274-1 Outline The Cancer Genome Atlas (TCGA) Genomic Data Commons

More information

DeSigN: connecting gene expression with therapeutics for drug repurposing and development. Bernard lee GIW 2016, Shanghai 8 October 2016

DeSigN: connecting gene expression with therapeutics for drug repurposing and development. Bernard lee GIW 2016, Shanghai 8 October 2016 DeSigN: connecting gene expression with therapeutics for drug repurposing and development Bernard lee GIW 2016, Shanghai 8 October 2016 1 Motivation Average cost: USD 1.8 to 2.6 billion ~2% Attrition rate

More information

Standardize and Optimize. Trials and Drug Development

Standardize and Optimize. Trials and Drug Development Informatics Infrastructure to Standardize and Optimize Quantitative Imaging in Clinical Trials and Drug Development Daniel L. Rubin, MD, MS Assistant Professor of Radiology Member, Stanford Cancer Center

More information

Tumor mutational burden and its transition towards the clinic

Tumor mutational burden and its transition towards the clinic Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress

More information

Next generation diagnostics Bringing high-throughput sequencing into clinical application

Next generation diagnostics Bringing high-throughput sequencing into clinical application Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no

More information

NGS ONCOPANELS: FDA S PERSPECTIVE

NGS ONCOPANELS: FDA S PERSPECTIVE NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration

More information

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels

6/12/2018. Disclosures. Clinical Genomics The CLIA Lab Perspective. Outline. COH HopeSeq Heme Panels Clinical Genomics The CLIA Lab Perspective Disclosures Raju K. Pillai, M.D. Hematopathologist / Molecular Pathologist Director, Pathology Bioinformatics City of Hope National Medical Center, Duarte, CA

More information

NGS IN ONCOLOGY: FDA S PERSPECTIVE

NGS IN ONCOLOGY: FDA S PERSPECTIVE NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for

More information

38 Int'l Conf. Bioinformatics and Computational Biology BIOCOMP'16

38 Int'l Conf. Bioinformatics and Computational Biology BIOCOMP'16 38 Int'l Conf. Bioinformatics and Computational Biology BIOCOMP'16 PGAR: ASD Candidate Gene Prioritization System Using Expression Patterns Steven Cogill and Liangjiang Wang Department of Genetics and

More information

Data mining with Ensembl Biomart. Stéphanie Le Gras

Data mining with Ensembl Biomart. Stéphanie Le Gras Data mining with Ensembl Biomart Stéphanie Le Gras (slegras@igbmc.fr) Guidelines Genome data Genome browsers Getting access to genomic data: Ensembl/BioMart 2 Genome Sequencing Example: Human genome 2000:

More information

SALSA MLPA probemix P315-B1 EGFR

SALSA MLPA probemix P315-B1 EGFR SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional

More information

MY LUNG CANCER CARE PLAN

MY LUNG CANCER CARE PLAN MY LUNG CANCER CARE PLAN MANAGE DIAGNOSIS TRACK TREATMENTS & APPOINTMENTS MONITOR SYMPTOMS FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers We are Free

More information

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D.

Clinical Biomarker in Kidney Cancer. Maria Nirvana Formiga, M.D., Ph.D. Clinical Biomarker in Kidney Cancer Maria Nirvana Formiga, M.D., Ph.D. Disclosures I am on the Speaker s Bureau with Pfizer and Bayer Clinical trials of BMS and Pfizer Kidney Cancer 70% new cases in developed

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer

More information

Reporting TP53 gene analysis results in CLL

Reporting TP53 gene analysis results in CLL Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review

More information

The Cancer Genome Atlas & International Cancer Genome Consortium

The Cancer Genome Atlas & International Cancer Genome Consortium The Cancer Genome Atlas & International Cancer Genome Consortium Session 3 Dr Jason Wong Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 31 st July 2014 1

More information

The Role of Next Generation Sequencing in Solid Tumor Mutation Testing

The Role of Next Generation Sequencing in Solid Tumor Mutation Testing The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories

More information

Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS

Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and

More information

University of Pittsburgh Cancer Institute UPMC CancerCenter. Uma Chandran, MSIS, PhD /21/13

University of Pittsburgh Cancer Institute UPMC CancerCenter. Uma Chandran, MSIS, PhD /21/13 University of Pittsburgh Cancer Institute UPMC CancerCenter Uma Chandran, MSIS, PhD chandran@pitt.edu 412-648-9326 2/21/13 University of Pittsburgh Cancer Institute Founded in 1985 Director Nancy Davidson,

More information

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff

5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff 5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late

More information

Identifying Novel Targets for Non-Small Cell Lung Cancer Just How Novel Are They?

Identifying Novel Targets for Non-Small Cell Lung Cancer Just How Novel Are They? Identifying Novel Targets for Non-Small Cell Lung Cancer Just How Novel Are They? Dubovenko Alexey Discovery Product Manager Sonia Novikova Solution Scientist September 2018 2 Non-Small Cell Lung Cancer

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials

More information

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis

Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis 5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory

More information

Introduction to the Partners Biobank Portal. December 2016

Introduction to the Partners Biobank Portal. December 2016 Introduction to the Partners Biobank Portal December 2016 Agenda About the Partners Biobank About the Biobank Portal Data Types in the Biobank Sample types DNA. Plasma and Serum Consent Genomic Data Health

More information

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%

More information

Clinical Grade Genomic Profiling: The Time Has Come

Clinical Grade Genomic Profiling: The Time Has Come Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation

More information

Contents. 1.5 GOPredict is robust to changes in study sets... 5

Contents. 1.5 GOPredict is robust to changes in study sets... 5 Supplementary documentation for Data integration to prioritize drugs using genomics and curated data Riku Louhimo, Marko Laakso, Denis Belitskin, Juha Klefström, Rainer Lehtonen and Sampsa Hautaniemi Faculty

More information

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients

Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs

More information

Hands-On Ten The BRCA1 Gene and Protein

Hands-On Ten The BRCA1 Gene and Protein Hands-On Ten The BRCA1 Gene and Protein Objective: To review transcription, translation, reading frames, mutations, and reading files from GenBank, and to review some of the bioinformatics tools, such

More information

SAGE. Nick Beard Vice President, IDX Systems Corp.

SAGE. Nick Beard Vice President, IDX Systems Corp. SAGE Nick Beard Vice President, IDX Systems Corp. Sharable Active Guideline Environment An R&D consortium to develop the technology infrastructure to enable computable clinical guidelines, that will be

More information

IPA Advanced Training Course

IPA Advanced Training Course IPA Advanced Training Course October 2013 Academia sinica Gene (Kuan Wen Chen) IPA Certified Analyst Agenda I. Data Upload and How to Run a Core Analysis II. Functional Interpretation in IPA Hands-on Exercises

More information

COSMIC - Catalogue of Somatic Mutations in Cancer

COSMIC - Catalogue of Somatic Mutations in Cancer COSMIC - Catalogue of Somatic Mutations in Cancer http://cancer.sanger.ac.uk/cosmic https://academic.oup.com/nar/articl e-lookup/doi/10.1093/nar/gkw1121 Data In Large-scale systematic screens Detailed

More information

Infrastructure for Clinical Data Exchange

Infrastructure for Clinical Data Exchange Infrastructure for Clinical Data Exchange Amy Abernethy, MD, PhD FEBRUARY 29 2016 Instrument Data Highly Structured Administrative Data Highly Structured Clinical Research Data Intentionally Structured

More information

Molecular Testing in Lung Cancer

Molecular Testing in Lung Cancer Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans

More information

Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics

Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics Director of Cytogenomics and Molecular Pathology Evidence-based

More information

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview

7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon

More information

Steps to Creating a New Workout Program

Steps to Creating a New Workout Program Steps to Creating a New Workout Program Step 1: Log into lab website: https://fitnessandhealthpromotion.ca/ a. If you have never logged in, use your FOL username without the @fanshaweonline.ca portion

More information

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards

From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards Perera-Bel et al. Genome Medicine (2018) 10:18 https://doi.org/10.1186/s13073-018-0529-2 RESEARCH From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular

More information

Comprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.

Comprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast. Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information

More information

Variant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18

Variant interpretation exercise. ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Variant interpretation exercise ACGS Somatic Variant Interpretation Workshop Joanne Mason 21/09/18 Format of exercise Compile a list of tricky variants across solid cancer and haematological malignancy.

More information

Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets

Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets Statistical Considerations for Novel Trial Designs: Biomarkers, Umbrellas and Baskets Bibhas Chakraborty, PhD Centre for Quantitative Medicine, Duke-NUS March 29, 2015 Personalized or Precision Medicine

More information

Introduction to LOH and Allele Specific Copy Number User Forum

Introduction to LOH and Allele Specific Copy Number User Forum Introduction to LOH and Allele Specific Copy Number User Forum Jonathan Gerstenhaber Introduction to LOH and ASCN User Forum Contents 1. Loss of heterozygosity Analysis procedure Types of baselines 2.

More information

I. Setup. - Note that: autohgpec_v1.0 can work on Windows, Ubuntu and Mac OS.

I. Setup. - Note that: autohgpec_v1.0 can work on Windows, Ubuntu and Mac OS. autohgpec: Automated prediction of novel disease-gene and diseasedisease associations and evidence collection based on a random walk on heterogeneous network Duc-Hau Le 1,*, Trang T.H. Tran 1 1 School

More information

Precision Medicine Knowledgebase (PMKB)

Precision Medicine Knowledgebase (PMKB) Precision Medicine Knowledgebase (PMKB) https://pmkb.weill.cornell.edu/ https://academic.oup.com/jamia/article/24/ 3/513/2418181/The-cancer-precisionmedicine-knowledge-base-for Click on this to expand/collapse

More information

David Tamborero, PhD

David Tamborero, PhD David Tamborero, PhD Lopez-Bigas' lab Study of Tumor Genomes Study of Tumor Genomes Study sequencing data of tumors to understand the biological mechanisms shaping the mutational processes observed at

More information

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser

Characterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why

More information

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:

More information

Journal: Nature Methods

Journal: Nature Methods Journal: Nature Methods Article Title: Network-based stratification of tumor mutations Corresponding Author: Trey Ideker Supplementary Item Supplementary Figure 1 Supplementary Figure 2 Supplementary Figure

More information

Data Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis

Data Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis February, 13th 2018 Data Sharing Consortiums and Large Datasets to Inform Cancer Diagnosis Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies:

More information

Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer

Cancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:

More information

Comprehensive genomic profiling for various solid tumors

Comprehensive genomic profiling for various solid tumors Content Highlight Test Specification Test Content Performance Validation Test Report I II III IV V The NovoPM TM comprehensive cancer genomic profiling test Comprehensive genomic profiling for various

More information

Oncofocus. Patient Test Report

Oncofocus. Patient Test Report Oncofocus Patient Test Report Lead Clinical Scientist: Keeda Snelson Senior BMS: Tiffany Haddow Date: 08 Feb 2017 1 of 6 Comment: The DNA and RNA extracted from this sample were of optimal quantity. The

More information

A Simple Pipeline Application for Identifying and Negating SNOMED CT in Free Text

A Simple Pipeline Application for Identifying and Negating SNOMED CT in Free Text A Simple Pipeline Application for Identifying and Negating SNOMED CT in Free Text Anthony Nguyen 1, Michael Lawley 1, David Hansen 1, Shoni Colquist 2 1 The Australian e-health Research Centre, CSIRO ICT

More information

Lipid annotation with MS2Analyzer. Yan Ma 10/24/2013

Lipid annotation with MS2Analyzer. Yan Ma 10/24/2013 Lipid annotation with MS2Analyzer Yan Ma 10/24/2013 Checklist before you start You need to have: 1.A computer with Java environment and Office(2003 or higher) 2.MS/MS spectra in MGF files 3.Latest version

More information

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?

1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011? Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations

More information

1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli

1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy

More information

Evolution of Pathology

Evolution of Pathology 1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy

More information

Re: NCI Request for Information, Strategies for Matching Patients to Clinical Trials (NOT-CA )

Re: NCI Request for Information, Strategies for Matching Patients to Clinical Trials (NOT-CA ) American Cancer Society Cancer Action Network 555 11 th Street, NW Suite 300 Washington, DC 20004 202.661.5700 www.acscan.org Norman E. Sharpless, M.D. Director National Cancer Institute 9609 Medical Center

More information

EGFRIndb: Epidermal Growth Factor Receptor Inhibitor database

EGFRIndb: Epidermal Growth Factor Receptor Inhibitor database EGFRIndb: Epidermal Growth Factor Receptor Inhibitor database Inderjit S Yadav 1,3, Harinder Singh 2, Mohd. Imran Khan 1, Ashok Chaudhury 3, G.P.S. Raghava 2 and Subhash M. Agarwal 1 * 1 Bioinformatics

More information

A Method for Analyzing Commonalities in Clinical Trial Target Populations

A Method for Analyzing Commonalities in Clinical Trial Target Populations A Method for Analyzing Commonalities in Clinical Trial Target Populations Zhe (Henry) He 1, Simona Carini 2, Tianyong Hao 1, Ida Sim 2, and Chunhua Weng 1 1 Department of Biomedical Informatics, Columbia

More information

LibreHealth EHR Student Exercises

LibreHealth EHR Student Exercises LibreHealth EHR Student Exercises 1. Exercises with Test Patients created by students a. Create a new Encounter using the Bronchitis form (template) i. While your patient s chart is open, go to either

More information

Semi-Automatic Construction of Thyroid Cancer Intervention Corpus from Biomedical Abstracts

Semi-Automatic Construction of Thyroid Cancer Intervention Corpus from Biomedical Abstracts jsci2016 Semi-Automatic Construction of Thyroid Cancer Intervention Corpus from Biomedical Wutthipong Kongburan, Praisan Padungweang, Worarat Krathu, Jonathan H. Chan School of Information Technology King

More information

The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies

The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies Patterson et al. Human Genomics (2016) 10:4 DOI 10.1186/s40246-016-0061-7 PRIMARY RESEARCH Open Access The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted

More information

Using the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview

Using the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview Using the NIH Collaboratory's and PCORnet's distributed data networks for clinical trials and observational research - A preview Millions of people. Strong collaborations. Privacy first. Jeffrey Brown,

More information

Chapter 12 Conclusions and Outlook

Chapter 12 Conclusions and Outlook Chapter 12 Conclusions and Outlook In this book research in clinical text mining from the early days in 1970 up to now (2017) has been compiled. This book provided information on paper based patient record

More information

The Expanding Value of Biomarkers in NSCLC Treatment

The Expanding Value of Biomarkers in NSCLC Treatment Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/closing-gaps-nsclc/the-expanding-value-of-biomarkers-in-nsclctreatment/10283/

More information

December 13, The Future Reimbursement Environment for NGS for Oncology

December 13, The Future Reimbursement Environment for NGS for Oncology WELCOME! Today s Speaker Mr. Mathews has worked on a variety of diagnostic reimbursement projects involving the analysis, development, and implementation of coding, coverage, and payment strategies for

More information

Phenotype analysis in humans using OMIM

Phenotype analysis in humans using OMIM Outline: 1) Introduction to OMIM 2) Phenotype similarity map 3) Exercises Phenotype analysis in humans using OMIM Rosario M. Piro Molecular Biotechnology Center University of Torino, Italy 1 MBC, Torino

More information

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The NSABP Foundation

More information

Automatic Context-Aware Image Captioning

Automatic Context-Aware Image Captioning Technical Disclosure Commons Defensive Publications Series May 23, 2017 Automatic Context-Aware Image Captioning Sandro Feuz Sebastian Millius Follow this and additional works at: http://www.tdcommons.org/dpubs_series

More information

Genome. Institute. GenomeVIP: A Genomics Analysis Pipeline for Cloud Computing with Germline and Somatic Calling on Amazon s Cloud. R. Jay Mashl.

Genome. Institute. GenomeVIP: A Genomics Analysis Pipeline for Cloud Computing with Germline and Somatic Calling on Amazon s Cloud. R. Jay Mashl. GenomeVIP: the Genome Institute at Washington University A Genomics Analysis Pipeline for Cloud Computing with Germline and Somatic Calling on Amazon s Cloud R. Jay Mashl October 20, 2014 Turnkey Variant

More information

Facts from text: Automated gene annotation with ontologies and text-mining

Facts from text: Automated gene annotation with ontologies and text-mining 1. Workshop des GI-Arbeitskreises Ontologien in Biomedizin und Lebenswissenschaften (OBML) Facts from text: Automated gene annotation with ontologies and text-mining Conrad Plake Schroeder Group (Bioinformatics),

More information

Structural Variation and Medical Genomics

Structural Variation and Medical Genomics Structural Variation and Medical Genomics Andrew King Department of Biomedical Informatics July 8, 2014 You already know about small scale genetic mutations Single nucleotide polymorphism (SNPs) Deletions,

More information

IMPaLA tutorial.

IMPaLA tutorial. IMPaLA tutorial http://impala.molgen.mpg.de/ 1. Introduction IMPaLA is a web tool, developed for integrated pathway analysis of metabolomics data alongside gene expression or protein abundance data. It

More information

Semantic Alignment between ICD-11 and SNOMED-CT. By Marcie Wright RHIA, CHDA, CCS

Semantic Alignment between ICD-11 and SNOMED-CT. By Marcie Wright RHIA, CHDA, CCS Semantic Alignment between ICD-11 and SNOMED-CT By Marcie Wright RHIA, CHDA, CCS World Health Organization (WHO) owns and publishes the International Classification of Diseases (ICD) WHO was entrusted

More information

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making

Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram

More information

DPV. Ramona Ranz, Andreas Hungele, Prof. Reinhard Holl

DPV. Ramona Ranz, Andreas Hungele, Prof. Reinhard Holl DPV Ramona Ranz, Andreas Hungele, Prof. Reinhard Holl Contents Possible use of DPV Languages Patient data Search for patients Patient s info Save data Mandatory fields Diabetes subtypes ICD 10 Fuzzy date

More information

Clonal Evolution of saml. Johnnie J. Orozco Hematology Fellows Conference May 11, 2012

Clonal Evolution of saml. Johnnie J. Orozco Hematology Fellows Conference May 11, 2012 Clonal Evolution of saml Johnnie J. Orozco Hematology Fellows Conference May 11, 2012 CML: *bcr-abl and imatinib Melanoma: *braf and vemurafenib CRC: *k-ras and cetuximab Esophageal/Gastric: *Her-2/neu

More information

MET skipping mutation, EGFR

MET skipping mutation, EGFR New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM

More information

Liquid biopsy: the experience of real life case studies

Liquid biopsy: the experience of real life case studies Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal

More information

Lung Cancer Concept Annotation from Spanish Clinical Narratives

Lung Cancer Concept Annotation from Spanish Clinical Narratives Lung Cancer Concept Annotation from Spanish Clinical Narratives Marjan Najafabadipour 1, [0000-0002-1428-9330], Juan Manuel Tuñas 1[0000-0001-8241-5602], Alejandro Rodríguez-González 1,2,* [0000-0001-8801-4762]

More information

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation

NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department

More information

Disclosures Genomic testing in lung cancer

Disclosures Genomic testing in lung cancer Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing

More information